Abstract
Get full access to this article
View all access options for this article.
References
1.Pfizer and Sangamo Therapeutics . Pfizer and Sangamo announce updated Phase 1/2 results showing sustained factor VIII activity levels and no bleeding events or factor usage in 3e13 vg/kg cohort following giroctocogene fitelparvovec (SB-525) gene therapy. June 18, 2020. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-sangamo-announce-updated-phase-12-results/ (last accessed
June 23 , 2020
).
2.uniQure and CSL Behring . uniQure announces license agreement with CSL Behring to commercialize hemophilia B gene therapy. June 24, 2020. https://www.globenewswire.com/news-release/2020/06/24/2052987/0/en/uniQure-Announces-License-Agreement-with-CSL-Behring-to-Commercialize-Hemophilia-B-Gene-Therapy.html (last accessed
June 25 , 2020
).
3.Dyno Therapeutics . Dyno Therapeutics announces ocular collaboration with Novartis to develop improved gene therapies with AAV vectors based on AI technology. May 11, 2020. https://www.dynotx.com/news/press-releases/dyno-therapeutics-announces-ocular-collaboration-with-novartis-to-develop-improved-gene-therapies-with-aav-vectors-based-on-ai-technology/ (last accessed
June 23 , 2020
).
4.Dyno Therapeutics . Sarepta Therapeutics and Dyno Therapeutics announce agreement to develop next-generation gene therapy vectors for muscle diseases. May 11, 2020. https://www.dynotx.com/news/press-releases/sarepta-therapeutics-and-dyno-therapeutics-announce-agreement-to-develop-next-generation-gene-therapy-vectors-for-muscle-diseases/ (last accessed
June 23 , 2020
).
5.Dyno Therapeutics . Dyno Therapeutics emerges from stealth to transform gene therapy using artificial intelligence. May 11, 2020. https://www.dynotx.com/news/press-releases/dyno-therapeutics-emerges-from-stealth-to-transform-gene-therapy-using-artificial-intelligence/ (last accessed
June 23 , 2020
).
6.Sana Biotechnology . Sana Biotechnology announces completion of initial financing. June 23, 2020. https://sana.com/sana-biotechnology-announces-completion-of-initial-financing/ (last accessed
June 23 , 2020
).
7.Sarepta Therapeutics . Sarepta Therapeutics and Codiak BioSciences collaborate to research and develop exosome-based therapeutics for rare diseases. June 18, 2020. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-and-codiak-biosciences-collaborate-research (last accessed
June 24 , 2020
).
8.Sarepta Therapeutics . Sarepta Therapeutics and Selecta Biosciences enter into research license and option agreement for Selecta's ImmTOR immune tolerance platform in neuromuscular diseases. June 18, 2020. https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-and-selecta-biosciences-enter-research (last accessed
June 24 , 2020
).
9.Akouos, Inc. Prospectus . Filed June 25, 2020. https://investors.akouos.com/static-files/2a0c19c4-4627-4851-8bce-fe5a2c100c58 (last accessed
July 7 , 2020
).
10.Lysogene . Lysogene announces important updates on AAVance phase 2/3 clinical trial with LYS-SAF302 in MPS IIIA. June 5, 2020. https://www.businesswire.com/news/home/20200604005805/en/Lysogene-announces-important-updates-AAVance-phase-23 (last accessed
June 23 , 2020
).